HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces That A Class Action Lawsuit Has Been Filed Against Humacyte, Inc. And Encourages Investors To Contact The Firm
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces That A Class Action Lawsuit Has Been Filed Against Humacyte, Inc. And Encourages Investors To Contact The Firm . (MENAFN - GlobeNewsWire - Nasdaq) NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit ...
América - MenaFN
(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or the“Company”) (NASDAQ: HUMA) in the United States District Court for the Middle District of North Carolina on behalf of all persons and entities who purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024, both dates inclusive (the“Class Period”). Investors have until January 17, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose to investors: (1) that the Company's Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing; (2) that the FDA's review of the BLA would be delayed while Humacyte remediated these deficiencies; and (3) that, as a result, there was a substantial risk to FDA approval of ATEV for vascular trauma; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you purchased or otherwise acquired Humacyte shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at ... , telephone at (212) 355-4648, or by filling out this contact form . There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Marion Passmore, Esq.

(212) 355-4648

...
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108925306/HUMACYTE-ALERT-Bragar-Eagel-Squire-PC-Announces-That-A-Class-Action-Lawsuit-Has-Been-Filed-Against-Humacyte-Inc-And-Encourages-Investors-To-Contact-The-Firm
2024-11-25
rss
(MENAFN - GlobeNewsWire - Nasdaq) NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit ...
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces That A Class Action Lawsuit Has Been Filed Against Humacyte, Inc. And Encourages Investors To Contact The Firm